SXR Labs
📞 020 3148 8876 ✉️ support@sxrlabs.com
Advancing pulmonary medicine research
Our respiratory program encompasses trials for asthma, COPD, pulmonary fibrosis, and other lung diseases. We employ advanced pulmonary function testing and imaging to assess treatment efficac
CFTR: Cystic Fibrosis Transmembrane Conductance Regulator, the defective protein in Cystic Fibrosis responsible for abnormal mucus production and lung damage.
IL-4/IL-13: Interleukins driving Type 2 inflammation in severe asthma, targeted by biologics like dupilumab.
Mucus Production Pathways: Molecular mechanisms driving excessive mucus in COPD and chronic bronchitis.
CFTR Modulators: Small molecules (ivacaftor, elexacaftor/tezacaftor/ivacaftor combinations) that correct or enhance the function of defective CFTR protein.
Biologics for Asthma: Anti-IL-4/IL-13, anti-IL-5, and anti-IgE antibodies for severe, uncontrolled asthma.
Bronchodilators: Long-acting beta-agonists (LABAs) and muscarinic antagonists (LAMAs) for COPD and asthma.
Inhaled AAV Vectors: Major research focus for Cystic Fibrosis, delivering functional CFTR gene directly to lung epithelial cells via inhalation. Lentiviral Vectors: Under investigation for delivering corrective genes to lung tissue in genetic respiratory disorders. mRNA Delivery: Exploring lipid nanoparticle-mediated mRNA delivery to lungs for temporary protein replacement therapy.
We utilize spirometry, plethysmography, DLCO testing, exercise testing, and high-resolution CT to comprehensively evaluate respiratory function and disease progression.
Respiratory research thrives on coordinated expertise in pulmonary function assessment. Clinical Trials Management coordinates complex pulmonary function testing protocols including spirometry, plethysmography, and exercise testing with certified respiratory technicians. Regulatory Affairs navigates respiratory-specific regulatory requirements for both device and pharmaceutical submissions. Data Management captures intricate lung function data, imaging results, and patient diary information with precision. Biostatistics analyzes pulmonary endpoints including FEV1, exacerbation rates, and quality of life measures. Quality Assurance ensures standardization of pulmonary function equipment, while Medical Writing translates complex respiratory data into clear regulatory documents.
Contact us to discuss how we can support your respiratory clinical trials.